Spinraza or Zolgensma Denied by Insurance? How to Appeal (SMA Treatment Guide)

Spinraza (nusinersen) and Zolgensma (onasemnogene abeparvovec) are transformative treatments for spinal muscular atrophy (SMA) — a rare, devastating neuromuscular disease. With Zolgensma costing over $2 million per dose and Spinraza over $750,000 in the first year, insurance denials are common and profoundly consequential. Here's how to fight back.

Spinal Muscular Atrophy (SMA) and FDA-Approved Treatments

SMA is caused by mutations in the SMN1 gene, leading to progressive motor neuron degeneration. It's the leading genetic cause of infant death. There are four types based on severity (Types 1–4), with Type 1 being the most severe (onset before 6 months, inability to sit).

Three FDA-approved SMA treatments:

Spinraza (nusinersen) — Biogen:

• FDA approved December 2016 (first SMA treatment approved)
• Intrathecal (spinal) injection given at weeks 0, 2, 4, and 8, then every 4 months
• Mechanism: antisense oligonucleotide that increases SMN protein production
• Approved for all SMA types and ages
• Annual cost after loading doses: ~$375,000/year

Zolgensma (onasemnogene abeparvovec) — Novartis Gene Therapies:

• FDA approved May 2019
• One-time IV infusion gene therapy
• Mechanism: delivers functional copy of SMN1 gene via AAV9 vector
• FDA-approved for children under 2 years with SMA
• Cost: ~$2.1 million (one-time dose)

Evrysdi (risdiplam) — Genentech/Roche:

• FDA approved August 2020
• Daily oral liquid — taken at home, not requiring intrathecal injection
• Similar mechanism to Spinraza (splicing modifier)
• Approved for patients 2 months and older with SMA
• Annual cost: ~$340,000

Why Insurers Deny SMA Treatments

Age restrictions: For Zolgensma, FDA approval is for children under 2 years. Some plans deny for children over 2 even when off-label use may be considered.

Genetic testing not documented. All three treatments require confirmed SMN1 deletion or mutation (typically 0 copies of SMN1 gene). If complete genetic workup isn't in the PA request, denial follows.

Severity not documented. PA criteria often require specific SMA type documentation and functional assessment (CHOP-INTEND, HFMSE, MFM32 scores).

"Experimental/investigational." Wrong — all three treatments have full FDA approval.

Only one treatment covered. Some plans allow only one SMA therapy; switching from Spinraza to Evrysdi (or vice versa) may require justification.

Genetic carrier status insufficient. Presymptomatic infants identified through newborn screening: some insurers initially question whether to treat before symptoms — but early treatment (before symptom onset) produces dramatically better outcomes.

Building Your SMA Appeal

Required Documentation

1. Genetic testing confirming SMA: SMN1 deletion analysis showing 0 copies of SMN1 (biallelic pathogenic variants); SMN2 copy number (important for prognosis and treatment planning)
2. SMA type classification: Type 1, 2, 3, or 4 (or presymptomatic, identified through newborn screening)
3. Functional assessment: CHOP-INTEND (for children), HFMSE, MFM32, or WHO motor milestones; recent EMG/NCS if applicable
4. Neurologist/neuromuscular specialist letter: Recommendation from pediatric neurologist or neuromuscular disease specialist affiliated with an academic medical center or SMA Center of Excellence (neuromuscular specialist carries weight in appeals)
5. Age of the patient: For Zolgensma, confirm age <24 months (or clinical trial setting if older)

Clinical Arguments

"Early treatment is best" argument: For presymptomatic infants: research consistently shows treatment before symptom onset leads to dramatically better outcomes compared to treatment after symptom onset. The NURTURE trial showed that presymptomatic SMA infants treated with Spinraza achieved and maintained normal motor milestones. Delaying treatment pending administrative processes allows irreversible motor neuron loss.

Newborn screening programs: Many states now include SMA in newborn screening panels. Denial of treatment for newborn-screen-identified infants conflicts with the public health intent of early detection programs.

Natural history argument: Without treatment, SMA Type 1 results in death or permanent ventilator dependency by age 2. SMA Types 2 and 3 result in progressive loss of function. The severity and progression of untreated SMA makes treatment urgency clear.

Zolgensma vs. Spinraza vs. Evrysdi Selection

Your neurologist should document why the specific treatment was chosen:

• Zolgensma: Preferred for children under 2 — one-time treatment vs. lifelong injections; strong efficacy in Type 1 SMA before symptom onset; cost is higher but long-term cost may be comparable to 20+ years of Spinraza/Evrysdi
• Spinraza: Effective across all ages and SMA types; established 7+ year safety and efficacy data
• Evrysdi: Oral administration — no intrathecal injections; important for patients with scoliosis or spinal access difficulties; convenient for ongoing treatment

If the plan requires a different SMA drug than prescribed, document why the physician's choice is clinically superior for this specific patient.

Request Expedited Review

SMA is a rapidly progressive disease in infants. Request expedited appeal review explicitly:

• "Delay of treatment for [Type 1 SMA / presymptomatic SMA] will cause irreversible motor neuron loss and may result in death or permanent ventilatory dependence"
• ERISA plans: expedited review within 72 hours for urgent situations
• ACA marketplace plans: same expedited review rights

Manufacturer Patient Assistance

Biogen (Spinraza):

• Biogen SMA Care patient assistance program
• Copay assistance available for commercially insured patients

Novartis Gene Therapies (Zolgensma):

• Novartis Patient Assistance Now Oncology (for rare disease/gene therapy access)
• AveXis (Novartis subsidiary) has a managed access program
• Zolgensma has an outcomes-based payment model available in some circumstances

Genentech (Evrysdi):

• Genentech Access Solutions patient assistance

Cure SMA (curesma.org): Patient advocacy organization with insurance navigation resources and access to advocacy support.

Sample Appeal Language

"I am appealing the denial of [Spinraza/Zolgensma/Evrysdi] for spinal muscular atrophy Type [X] in a [age] patient with confirmed biallelic SMN1 deletion (0 copies of SMN1 gene, genetic report attached). My patient's pediatric neurologist, Dr. [Name], has determined that [treatment] is the medically necessary and appropriate FDA-approved therapy for this patient based on documented genetic confirmation and clinical assessment.

SMA is a fatal, rapidly progressive neuromuscular disease. Untreated SMA Type 1 results in death or permanent ventilatory dependence by age 2. [Treatment] is FDA-approved for this indication with demonstrated efficacy in clinical trials. I am requesting expedited review as delay of treatment will result in irreversible motor neuron loss and increased functional impairment. I respectfully request immediate reversal of this denial."

Fight Back With ClaimBack

ClaimBack generates SMA treatment appeal letters with genetic documentation requirements, NURTURE/ENDEAR trial data, and expedited urgency arguments for infant SMA cases.

Free analysis. Appeal letter from USD 12.

Related Reading

• Prior Authorization Denied: How to Appeal" class="auto-link">Prior Authorization Denied? How to Appeal
• What Is Medical Necessity and How to Prove It
• Common Reasons Insurance Claims Are Denied